HK’s Immuno Cure nabs $12m in first close of Series A led by Gobi Partners GBA

Hong Kong-based clinical-stage biotechnology group Immuno Cure BioTech has nabbed $12 million from Gobi Partners GBA for the first close of its Series A funding round, the company said on Thursday.